Study Selection The trials we included met the following criteria: (1) RCTs that compared GLP-1 receptor agonist with a placebo or active control (other antidiabetic drugs or insulin), (2) patients with type 2 diabetes, type 1 diabetes, prediabetes, overweight or obesity, (3) with durations of at least 24 weeks, and (4) reported the occurrence of at least one case of various thyroid disorders as adverse events
Apply a cold compress for the first 10 minutes after injection if needed
& Petri, S
Switching should not be driven by price alone clinical suitability, tolerability and patient preference remain paramount
In-office and take-home medication options are available based on what's right for you
Current medications like Ozempic or Zepbound only hit one or two of those pathways, which is likely why early data is showing more dramatic results. New research on retatrutide benefits for weight loss According to NBC News , the newest phase 3 clinical trial found that people taking retatrutide lost up to 85 pounds, essentially 30 percent of their body weight, which is not too dissimilar to the percentage of body weight people lose after bariatric surgery, which is 25 to 35 percent within one to two years, per NBC News referencing data from Circulation Research
